← Eichor
Condition: Blinatumomab Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Blinatumomab

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Phase 2/Phase 3 · 12 location(s) · Merck Sharp & Dohme LLC · NCT07570173Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
Phase 2 · 85 location(s) · Goethe University · NCT06061094Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL
Phase 1 · 1 location(s) · Liping Dou · NCT07677878Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06554626Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Lif
Phase 3 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT05029531Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leuke
Phase 2 · 1 location(s) · Northside Hospital, Inc. · NCT05519579A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants
Phase N/A · 2 location(s) · Arkansas Children's Hospital Research Institute · NCT07422337Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
Phase 2/Phase 3 · 27 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06882057Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual C
Phase 2 · 113 location(s) · National Cancer Institute (NCI) · NCT06317662ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
Phase 1 · 4 location(s) · Marlise Luskin, MD · NCT03595917A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Phase 2 · 57 location(s) · Amgen · NCT06570798Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
Phase 3 · 115 location(s) · Martin Schrappe · NCT03643276Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoi
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT07105579Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+
Phase 1/Phase 2 · 1 location(s) · Novartis Pharmaceuticals · NCT07387926Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem C
NA · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT07003737A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Phase 3 · 138 location(s) · Mats Heyman · NCT04307576Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)
Phase 2 · 1 location(s) · West Virginia University · NCT07222579Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03263572Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06393985Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02877303Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acut
Phase 1/Phase 2 · 2 location(s) · M.D. Anderson Cancer Center · NCT06308588Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
Phase 1 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06507514Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05645718Blinatumomab for CNI-Resistant/Intolerant SRNS in Children
Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT06607991Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07564453Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, o
Phase 2 · 278 location(s) · National Cancer Institute (NCI) · NCT03739814Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
Phase 2 · 1 location(s) · Medical College of Wisconsin · NCT04746209Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation
Phase 4 · 1 location(s) · Suping ZHANG · NCT06339775Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06287229Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refrac
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT07133997
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.